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Abstract 
Pancreas  transplantation  is  the  definite  treatment  for  type  1  diabetes  that  enables  the 
achievement  of  long-term  normoglycemia  and  insulin  independence.  However 
Post-Transplantation Pancreatitis (PTP) due to ischemia reperfusion (IR) injury and preser-
vation  is  a  major  complication  in  pancreas  transplantation.  Owning  the  potential  an-
ti-inflammatory effect of Cisplatin (Cis) in liver IR injury, we have examined if Cis could at-
tenuate PTP using a murine model. We found that Cis is able to prevent inflammatory re-
sponse in PTP. Pretreatment of Cis in recipient mice reduce the impairments of the grafts and 
hyperamylasimea in the recipients. We documented that the protective mechanism of Cis in 
PTP involves improvement of microcirculation, reduction of the mononuclear cellular infil-
tration  and  apoptosis,  suppression  of  inflammatory  cytokine-cascade  and  inhibition  of 
translocation of high-motility group box protein-1 (HMGB-1) from nucleus to cytoplasm. In 
short, our study demonstrated that pretreatment of Cis in recipients may reduce the onset of 
PTP in pancreas transplantation. 
Key words: Cisplatin, Pancreatitis, Ischemia reperfusion injury, High-motility group box protein-1, 
Intravital ﬂuorescence microscopy. 
Introduction 
 Pancreas  transplantation  is  the  definite  treat-
ment for type 1 diabetes that enables the achievement 
of  long-term  normoglycemia  and  insulin  independ-
ence. The technique had evolved many years since the 
first  clinical  transplant  in  1966,  by  the  team  of  Dr. 
Kelly  and  Dr.  Lillehei  [1,2].  However,  a  variety  of 
post-transplant complications, such as immunological 
rejection, recurrent autoimmunity and inflammation 
has been reported. Among of them PTP remains the 
main cause of intra-abdominal abscess, fatal infection 
and  other  motilities  [3,4].  Unlike  acute  bilogenic  or 
alcoholic pancreatitis induced by exocrine occlusion 
or  chemical  stimuli,  organ  preservation  and  ische-
mia/reperfusion (IR) injury is the primary cause for 
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PTP.  
The reoxygenation of the hypoxic pancreatic ac-
ini after IR triggers the inflammatory mediators and 
microcirculatory  disturbance  [5].  The  physiological 
alterations of PTP resemble general pancreatitis, but 
are featured by the aggressive progression and poor 
respond to treatment [6,7]. Several factors, such im-
munesuppression, transplant site, rejection and septic 
tendency, have been showed to contribute to the pa-
thology of the PTP [8]. Currently there are many at-
tempts in searching potential agents that are able to 
mitigate PTP. 
 Cisplatin (CIS) has been used as chemotherapy 
drug  in  the  treatment  of  cancers  for  more  than  30 
years  [9].  It  causes  conformational  changes  in  the 
double  helix  of  DNA  that  contains  binding  site  of 
HMGB-1  (high-motility  group  box  protein  1)  [9]. 
Crosslink of DNA by Cis results in interfering of mi-
tosis and activating apoptosis of target cell. Interest-
ingly, Recent reports has indicated that Cis at optimal 
low does is shown to have a protective effect for is-
chemia  reperfusion  injury  in  murine  liver  and 
hepatocytes  subjected  to  hypoxic  exposure  [9].  The 
mechanism  was  partially  due  to  the  inhibition  of 
HMGB-1 releasing from the nucleus  of the hypoxic 
cells [9].  
The  protective  effects  of  Cis  in  prevention  of 
liver  IR  injury  was  intriguing,  thus  provoking  our 
interests to examine its role in PTP. We modified a 
murine model of pancreas transplantation with pre-
served exocrine drainage, that can mimic the PT in 
human[6]. Using this model, we studied the protec-
tive effects of Cis on graft pancreatitis. We hypothe-
size that Cis might attenuate the graft impairments by 
inhibiting  the  local  inflammation  response  in  graft 
after PTP.  
Materials and methods 
Animals  
 Male Balb/c mice aged from 8 to 12 weeks, ob-
tained  from  Shanghai  Animal  Center  (Chinese 
Academy of Science, Shanghai, China), were used as 
size  matched  donor  and  recipient  pairs.  The  mice 
were housed in standard pathogen free condition and 
with free access to standard rodent food and water. 
All animal experiments were approved by the Animal 
Care Committee of Zhejiang University in accordance 
with the Principles of Laboratory Animal Care. 
Experiment design and surgical procedure 
Donor  operation:  Donor  pancreas  were  har-
vested from Balb/C mice by non-touch technique [6], 
the pancreatic head ligated but the main pancreatic 
duct open by catheterization. The grafts were stored 
in UW (University of Wisconsin solution) solution at 
4℃ for 16 h (Cold ischemia time of graft is 16 hours). 
Recipient  operation:  The  optimization  of  final 
dose selection and the time point for Cis pretreatment 
is  based  on  previous  study  by  Tsung’s  group.12h 
prior to recipient operation, mice were injected intra-
peritoneally 0.5ml PBS (Control group) or Cis at three 
different  dosages  (0.1mg/kg,  1  mg/kg,  and  10 
mg/kg; PBS was used for dissolve Cis. n=6 respec-
tively). Graft was implanted in the recipient’s cervical 
region by connecting the portal vein to the external 
jugular vein and the donor aortic segment to the ca-
rotid artery by cuff technique[6, 10]. 
Experiments:  Six  animals  were  used  in  each 
group.  Specimens  were  harvested  after  6  hours  of 
transplantation  and  cut  into  small  pieces  for  histo-
pathology,  immunohistochemistry,  Tunel  assay  and 
Western  blotting,  respectively;  Serum  was  collected 
for  amylase  assay.  Graft  microcirculation  was  ana-
lyzed by intravital ﬂuorescence microscopy (IVM) 2h 
after  reperfusion.  Flow  chart  and  the  experimental 
design were shown in Fig. 1. 
Agents and Antibodies 
 Cis was purchased from Sigma Inc., All the an-
tibodies used in this study are listed below: Apop-Tag 
Peroxidase  In  Situ  Apoptosis  Detection  Kit 
(cat#S7100;  Chemicon  International  Inc.,  Billerica, 
MA,  USA),  Anti-IL-1-beta  antibody 
(cat#ab9722,abcam,UK),  Anti-IL6  antibody 
(cat#ab6672,  abcam,UK),  Anti-TNF  alpha  antibody 
(cat#ab6671,  abcam,UK),  Mouse  Myeloperoxidase 
/MPO  Antibody(cat#  392105,  R&D  Systems,  Inc). 
Fuorescein-isothiocyanate-labeled  dextran  (FITC- 
dextran) was obtained from Sigma Chemical Co., St. 
Louis, MO, USA. 
Histopathology  
 Specimens  were  fixed  in  10%  formaldehyde 
over 24 hours, dehydrated and embedded in paraffin. 
5μm sections were made and stained with hematoxy-
lin and eosin (H&E). The sections were scored with 
Schmidt’s  method  for  inflammatory  infiltration,  in-
terstitial  edema,  acinar  cell  necrosis  and  hemor-
rhage-fat necrosis by independent pathologists [11]. 
Immunohistochemistry 
Specimens from histopathology were sectioned 
for  immunohistochemistry.  In  brief,  sections  (5μm) 
were  de-waxed  and  rehydration,  pancreas  sections 
were put in 3% H2O2 for 15 minutes to block endog-
enous  peroxidase  and  then  were  boiled  in  sodium 
citrate buffer pH 6.0 for 15 minutes. After incubated in Int. J. Biol. Sci. 2012, 8 
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5%  fetal  serum  phosphate  buffered  saline  for 
30minutes  at  room  temperature,  the  sections  were 
added with MPO antibodies at 1:50 dilution at 4°C 
overnight and in goat-anti rabbit secondary antibody 
at 1:500 dilution for 30 minutes at room temperature. 
Diaminobenzidine  were  applied  for  3  minutes  and 
then the sections were counterstained with hematox-
ylin. 
To improve the antigen retrieval, sections were 
boiled in sodium citrate buffer pH 6.0 for 15 min and 
incubated in 5% fetal serum phosphate buffered saline 
for 30 min at room temperature, and then incubated in 
HMGB-1 antibody at 1:200 dilution at 4°C overnight. 
At the second day Alexa-fluor donkey anti-rabbit IgG 
(Invitrogen) were applied to the section at 1:200 dilu-
tions for 30minutes at room temperature. After Dapi 
dye, the sections were washed three times with PBS 
and coverslipped with glycerol. Images were obtained 
by  LEICA  CTR  5500  (LEICA)  and  analyzed  by  im-
age-pro plus 6.0 software.  
Tunel assay 
The paraffin sections of specimens were stained 
for apoptotic cells by the Tunel assay using a com-
mercially available kit (Apop-Tag Peroxidase In Situ 
Apoptosis  Detection  Kit  S7100;  Chemicon  Interna-
tional Inc., Billerica, MA, USA). The Tunel assay was 
performed according to the manufacturer’s protocol. 
The results  were presented as the  mean  number of 
Tunel-positive cells per high power field. 
Amylase assay  
Six hours after reperfusion, blood samples were 
obtained from retrobulbar venous plexus and centri-
fuged at 3000 r/m for 15minutes and stored at -80°C 
before  analysis.  The  amylase  level  in  serum  was 
measured  using  an  Automated  Chemical  Analyzer 
(7600; Hitachi, Tokyo, Japan). 
Western Blotting  
Mice  from  each  group  were  sacrificed 6  hours 
after  reperfusion  and  half  of  pancreatic  grafts  were 
homogenized  in  lysis  buffer,  sonicated  and  centri-
fuged at 5,000 rpm. The extracts contain equal volume 
and  equal  protein  concentration  were  separated  by 
12% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to nitrocel-
lulose membranes. The membrane was blocked with 
5% fetal serum-Tris-buffered saline (TBS) with 0.1% 
Tween 20 (TBS-T) at room temperature for 2 hours. 
Then membranes were incubated in rabbit-anti mice 
polyclonal  HMGB-1,  IL-1,  IL-6  or  TNF-alpha  (dilu-
tion=1:1000) at 4°C overnight. After three washes of 
TBS-T the membranes were then incubated with goat 
anti-rabbit secondary antibody at (dilution=1:1500) at 
room temperature for 2 hours. Results were obtained 
by  KODAK  image  station  2000R  and  analyzed  by 
image-pro plus 6.0 software.  
 
Fig. 1. Flow chart and experiment design of pancreases transplantation. 
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Intravital ﬂuorescence microscopy (IVM) 
IVM was used to analyze graft microcirculation 
injury by means of functional capillary density (FCD) 
and capillary diameters (CD). Stationary of microcir-
culatory changes was conducted by quantification of 
functional  capillary  density  (FCD)  in  ten  randomly 
selected areas. Measurements were performed 120min 
after reperfusion (total time of ischemia-reperfusion 
for  IVM=16h  cold  ischemia  time  +  2h  reperfusion 
time). FCD, the length of red blood cell perfused ca-
pillaries per defined area (centimeters per square cen-
timeter), was at the vessel wall for at least 30 s. [12]. In 
brief, recipient mice were injected with Cis (1mg/kg) 
or  PBS  12h  before  transplantation.  Two  hours  after 
transplantation  (total  ischemia-perfusion  time  is  16 
hours), mice were placed in a prone position, and the 
pancreatic graft was placed on a slide in warm saline 
at  37°C.  Blood  perfusion  within  individual  micro 
vessels  was  examined  after  intravenous  injection  of 
ﬂuorescein-isothiocyanate-labeled  dextran  (FITC- 
dextran) at a dose of (i.v. 0.3 ml, 4 mg/ml) [12]. An 
equilibration period of 5 minutes was allowed before 
starting  the  microscopic  observation.  IVM  was  per-
formed  using  a  modified  Olympus  microscope 
(IX81WI;  Olympus  Optical  Corporation  GmbH, 
Hamburg,  Germany).  Filter  blocks  for  fluorescein 
(excitation 465–495 nm, emission >515 nm) and rho-
damine  (excitation  510–560  nm,  emission  >590  nm) 
were  used  for  epi-illumination  (Olympus),  and  the 
images  were  acquired  using  KAPPA  Image  Base 
software. Quantitative image analysis was performed 
with PicEd Cora (JOMESA, Munich, Germany) soft-
ware.  (More  detailed  technical  information  please 
refer to ref. [12]) 
Statistical analyses  
 All  statistics  have  been  calculated  using  the 
prism 5.01 software package (GraphPad Software 5.0, 
USA).  All  data  are  presented  as  mean  values 
±standard error of the mean (SEM). Analysis of vari-
ance (ANOVA) and T test of independent means were 
used  for  statistical  analysis.  Data  were  considered 
signiﬁcant at a level of p<0.05. 
Results 
Cis pretreatment attenuates PTP in Mice 
 Recipient Balb/c mice were given injections of 
PBS or Cis 12 hours before transplantation. Six hours 
after reperfusion (total time of ischemia-reperfusion is 
16h  cold  ischemia  time  plus  6h  reperfusion  time), 
specimens  were  harvested  and  were  subjected  for 
histological examination. Semi quantitative histolog-
ical scoring of interstitial edema, inflammation, acinar 
necrosis and hemorrhage-fat necrosis were measured 
using the method described by Schmidt et al [11]. The 
results showed that pretreatment of Cis in recipients 
display a reduction of local inflammation. The reduc-
tion of mononuclear cell infiltrates in parenchyma and 
perivascular regions of the grafts was very obvious 
when compared to the PBS control (Fig.2A-D). Semi 
quantitative assessment showed that the suppression 
of  inflammation  is  in  a  dose  dependent  manner 
(Fig.2E).  It  is  noteworthy  that  acinar  necrosis  and 
hemorrhage-fat  necrosis  were  not  observed  in  both 
PBS and Cis groups.  
Cis protects pancreas acinar cell from apop-
tosis after transplantation. 
 Next,  we  examine  if  Cis  prevents  acinar  cell 
apoptosis  in  pancreatic  grafts  after  transplantation. 
Using Tunel assay we found that pretreatment of Cis 
results  in  reduction  of  numbers  of  apoptotic  acinar 
cells (Fig. 3). It appears that only Cis at a dose over 
1mg/kg  can  achieve  significant  effect  evidenced  by 
the reduction of total cell counts of apoptotic cells per 
field.  This  result  suggested  that  Cis  at  the  optimal 
dose  of  1mg/kg  is  capable  to  protect  acinar  cell 
apoptosis (Fig. 3).  
Serum Amylase was marked reduced by pre-
treatment of Cis 
Serum amylase levels are widely accepted as an 
indicator of acinar cell necrosis and subsequent pan-
creatic tissue injury in pancreatitis [14]. Although we 
did  not  observe  obvious  acina  cell  necrosis  in  both 
PBS and Cis treatment groups, serum amylase may be 
changed due to the onset of PTP. To this end, we used 
serum amylase as a surrogate marker for protective 
effect in acinar cells. To examine if Cis has protective 
effect on acinar cells after transplantation, the levels of 
amylase in sera at 6 hours after transplantation were 
measured. The result showed that in comparison with 
the  PBS  control  group,  the  serum  amylase  was  re-
duced by pretreatment of Cis at a dose of 1mg/kg. 
However, Cis at doses of 0.1 and 10 mg/kg failed to 
achieve a significant effect on the levels of amylase 
(Fig. 4). The failure of dose response may reflect to the 
sensitivity of the serum amylase assay. Nevertheless, 
taking together with the histological assessment and 
apoptosis assays, we concluded that Cis pretreatment 
can reduce the severity of the post-transplant pancre-
atitis by the protection of acinar cell death and inhibi-
tion of local inflammation of the graft. 
Cis reduces the impairments of microcircula-
tion in grafts 
 Survival of graft after transplantation depends Int. J. Biol. Sci. 2012, 8 
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on the restoration of microcirculation. To quantify the 
dynamics  of  microcirculation  after  transplantation, 
we  have  used  IVM  in  real  time  to  measure  FCD 
(functional  capillary  density)  and  CD  (capillary  di-
ameters) 2 h after transplantation (total ischemia time 
16 hours plus reperfusion time 2 hours) in mice. Basic 
on  the  previous  studies  described  above,  we  have 
chosen  the  optimal  dose  of  1mg/kg  of  Cis  for  real 
time  IVM  experiments  [12-15].  Our  results  showed 
that in the recipients receiving PBS as control, the cold 
preserved grafts for 16-hour preservation plus 2 hours 
reperfusion after transplantation had relatively poor 
microcirculatory  (Fig  5A).  In  contrast,  pancreatic 
grafts with pretreatment of Cis under identical condi-
tion as to the control showed significant enrichment of 
the microcirculatory architecture compared with the 
PBS control group (Fig. 5B). Quantitative analysis of 
FCD and CD showed that while the CD remains un-
changed  (Fig.  5C),  the  FCD  was  significantly  in-
creased after treatment of Cis (Fig. 5D). Our results 
revealed that Cis may inhibit the occurrence of perfu-
sion disorders in the early period of PTP.  
 
Fig.  2.  Histopathology  of 
pancreatic  graft  after 
transplantation.  A)  PBS- 
control group. A large number 
of  leukocytes  infiltrated  into 
graft  (Black  arrow)  and  acinar 
cell  necrosis  (Red  arrow)  was 
observed  in  PBS  treated  con-
trols. B-D) Cis pretreated group 
(B=0.1mg/kg,  C=1.0mg/kg, 
D=10mg/kg).  Note  that  pre-
treatment  of  Cis  in  recipient 
displays  reduction  of  local  in-
flammation.  E)  Histological 
score  of  PTP.  Note  that  Cis 
significantly  inhibited 
graft-infiltrating  cells  in  a  dose 
depend  manner.  Inhibition  of 
acinar necrosis was also noticed. 
All  sections  harvested  from 
each  group  were  scored  with 
Schmidt’s  method  for  inflam-
matory  infiltration,  edema  for-
mation  by  three  independent 
pathologists [11]. N=6 mice per 
group. 
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Fig. 3. Tunel assay of acinar cells after transplantation. The staining of apoptotic cells by the Tunel method in graft. A) PBS-control 
group.  Pancreatic  acinar  cells  apoptosis  were  observed  in  PBS-control  group  (Arrow).  B-D)  Cis  pretreated  group  (B=0.1mg/kg, 
C=1.0mg/kg, D=10mg/kg). After pretreatment with Cis, the number of pancreatic acinar cell apoptosis (Arrow) was reduced. E) Number 
of apoptotic acinar cells in the graft. Note that Cis decreased the number of acinar cell apoptosis. Stationary of Tunel assay was conducted 
by quantification of apoptosis cell in 10 randomly high power fields. N=6 mice per group. Int. J. Biol. Sci. 2012, 8 
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Fig. 4. Serum Amylase level after transplantation. Serum amylase was measured 6-hr after pancreas transplantation. Cis de-
creased serum amylase level at a dose of 1.0mg/kg. N=6 mice per group. 
 
 
Fig. 5. Intravital fluorescence microscopy (IVM) of the graft. A) PBS-control group. IVM displayed severe perfusion dysfunction in 
grafts, the capillary density was significantly reduced by IR injure after transplantation. B) Cis pretreated group (1.0mg/kg). Cis pre-
treatment significantly improved graft microcirculation, a richer capillary network was observed (Arrow). C) Capillary diameters (CD) of 
pancreas exocrine tissue. D) Functional capillary density (FCD) of pancreas exocrine tissue. Note that FCD was significantly increased in 
Cis pretreated group. Original magnification: 350X. N=6 mice per group, each mice collected eight time points of data. 
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Cis pretreatment inhibits local inflammatory 
cell infiltration in graft.  
We  next  examine  neutrophil  or  monocytes  / 
macrophages sequestration in the graft. We proposed 
that myeloperoxidase (MPO) released by these cells 
may play an important role in the onset of PTP. To 
this end, we measured MPO activity in neutrophils, 
monocytes/macrophages in pancreatic grafts by im-
munohistochemistry.  The  result  showed  that  pre-
treatment of Cis in recipients display less MPO posi-
tive  cells  compared  with  the  PBS-transplanted  pan-
creas (Fig. 6A-D). Semi quantitative analyses of MPO 
positive  cells  per  field  demonstrated  that  pretreat-
ment  of  Cis  at  the  doses  between  0.1mg/kg  to  10 
mg/kg significantly (p=0.002) decreased the numbers 
of MPO positive cells (Fig. 6E). This result indicated 
that Cis significantly inhibits activity of neutrophils 
and monocytes.  
 
 
Fig. 6. Immunohistochemistry of MPO in Graft. Control group: a large number of MPO+ cells infiltrating into the acinar interstitial 
(Arrow). B-D) Cis pretreated groups. Pretreatment with Cis significantly reduced the MPO+ cells in different doses (B=0.1mg/kg, 
C=1mg/kg, D=10.0mg/kg). E) Numbers of infiltrated MPO + cells in the graft. Note that Cis reduced numbers of MPO + cells in pancreatic 
interstitial. Stationary of MPO immunohistochemistry was conducted by quantification of MPO+ cell in 10 randomly high power fields. N=6 
mice per group. Int. J. Biol. Sci. 2012, 8 
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Fig. 7. Level of inflammatory cytokines in graft extracts after transplantation. A)IL-1.B) IL-6.C) TNF-alpha. Note that the 
expression of IL-1, IL-6 and TNF-alpha in the pancreas graft was dropped after Cis. The results were expressed as ratio of gray value of 
Target band and the beat-Actin bend. N=6 mice per group. 
 
Cis inhibit the inflammatory cytokine-cascade 
after transplantation. 
Cascade of inflammatory cytokines is proved to 
be a critical step in IR injury and acute pancreatitis 
[16].  Using  tissue  extract  and  western  blotting,  we 
tested the tissue level of IL-1 (Fig.7A), IL-6 (Fig.7B), 
and  TNF-alpha  (Fig.7C)  in  pancreatic  graft  6  hour 
after transplantation. The result showed that protein 
expression of IL-1, IL-6 and TNF-alpha in the grafts 
was inhibited by the pretreatment of Cis in recipients. 
While the reduction of IL-1 and TNF-alpha expression 
did not achieve a statistical significance at the lower 
doses,  the  suppression  of  IL-6  expression  is  in  a 
dose-dependent manner. This variation may be due to 
the fate that cytokine cascade is a dynamic process, 
and thus a single time measurement at 6 hours may 
not be able to determine the dose dependent effect. 
Cis suppresses HMGB-1 translocation and ex-
pression in host inflammatory cells. 
Recent  studies  by  Cardinal  et al  demonstrated 
that  inhibition  of  HMGB-1  release  from  nuclear  to 
cytoplasm by Cis protects liver from IR induced in-
jury [9, 17]. To explore the potential mechanism by 
which Cis attenuates PTP, we examined the intracel-
lular localization and protein expression of HMGB-1 
using  immunofluorescence  staining  and  western 
blotting.  Immunofluorescence  demonstrated  that  in 
graft infiltrating inflammatory cells from the control 
group with pretreatment of PBS, HMGB1 is located 
predominantly in cytoplasm and less in nucleus. In 
contrast,  pretreatment  of  Cis  in  doses  between 
0.1mg/kg to 10mg/kg showed decreased cytoplasmic 
signal  and  increased  nuclear  location  of  HMGB-1. 
This result implies Cis prevented IR induced shuttling 
of  HMGB-1  from  nucleus  to  cytoplasm  (Fig.  8A-F). 
Next, we examined if Cis can reduce protein expres-
sion of HMGB-1. Western Blot analyses showed that 
pretreatment  with  Cis  also  evidently  decreases  the 
level  of  HMGB-1  in  tissue  extract  of  pancreas  graft 
(Fig. 8G-H).  
Discussion 
 PTP due to IR injury and poor preservation is a 
critical  complication  in  pancreas  transplantation.  In 
the present study, we find that pretreatment of Cis in 
recipient  mice attenuates  PTP as evident by the re-
duction of graft inflammatory response and the pro-
tection of acinar cell apoptosis. The protective effects 
by Cis may involve multiple steps including reduc-
tion of inflammatory cell infiltration and  activation, 
improvement  of  the  microcirculation,  inhibition  of 
inflammatory  cytokine-cascade  and  reduction  of 
HMGB-1 expression and translocation from nucleus 
to cytoplasm in graft-infiltrating inflammatory cells.  
Activated  graft-infiltrating  granulocytes  and 
monocytes/macrophages  release  various  cytokines 
and chemokines, which may cause pancreatic inter-
stitial  edema,  microcirculation  dysfunction,  acinar 
cells  apoptosis/  necrosis,  and  ultimately  lead  to  a 
severe PTP [18]. In our model, we used a modified 
non-touch  technique,  based  on  Masayuki  tori’s  de-
scription [6], which preserved exocrine drainage. We 
believe this mending the shortcoming from an occlu-
sion of pancreatic duct that leads to additional dam-
age of tissue. As a result, our model showed less ne-
crosis and hemorrhage after reperfusion, which cor-
responds the clinical transplants well [19].  
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Fig. 8. Intracellular staining and protein expression of HMGB-1 in graft. HMGB-1(Cy3-Red), cell nuclear (DAPI-Blue). A) 
Control group. Note that HMGB-1 is observed in cytoplasm (White arrow). B-D) Cis pretreatment group (B=0.1mg/kg, C=1mg/kg and, 
D=10mg/kg). Note that majority of HMGB-1 is located nuclear (Red Arrow) E) HMGB-1 release from nuclear of graft-infiltrating cell in 
Control group. F) HMGB-1 was retained in cell nuclear by pretreatment of Cis. G-H) Protein expression of HMGB-1.The protein ex-
pression of HMGB-1 in graft level was significantly reduced by the pretreatment of Cis. The results were expressed as ratio of gray value 
of target band and the beat-Actin bend. N=6 mice per group. 
 
Microcirculatory  dysfunction  had  been  consid-
ered to be an indicator for the severity of pancreati-
tis[20]. Several studies have used FCD as an indicator 
of the  quality  of tissue perfusion in various animal 
models [5, 21-25]. FCD is considered to be a sensitive 
real-time  indicator,  which  enable  to  reflect  the  per-
formance  of  functional  perfusion  of  the  tissue  [26]. 
Studies by Nolte et al have shown that FCD is able to Int. J. Biol. Sci. 2012, 8 
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yield  highly  reproducible,  user-independent  results 
under  physiologic  conditions  and  the  pathophysio-
logic  conditions  of  ischemia-reperfusion  in  various 
pancreas models [27]. Using FCD as the parameter for 
microcirculation, we showed that Cis may inhibit the 
occurrence  of  perfusion  disorders  during  the  early 
period of PTP. We postulated that the improvement of 
microcirculation evidenced by FCD may be due to the 
reduction of the inflammatory cell infiltration by Cis.  
MPO  and  the  cascade  release  of  inflammatory 
cytokines  including  TNF-alpha,  IL-1,  and  IL-6  are 
important  mediators  of  inflammation  which  play 
critical role in the pathogenesis of PTP. Our study has 
demonstrated that Cis not only inhibit inflammatory 
cell infiltration, but also suppress their activation by 
the release of MPO and inflammatory cytokines.  
It is believed that the release of HMGB-1 from 
nucleus is a trigger for the cascades of activation of the 
inflammation [28, 29]. Studies by Tsung et al showed 
that  Cis  treatment  benefits  to  the  prevention  of  he-
patic IR injury by reducing the inflammatory cell in-
filtration and the production of inflammatory media-
tors  [30,  31].  Indeed,  the  release  of  HMGB-1  was 
identified  as  an  early  event  in  the  pathogenesis  of 
organ IR impairments, followed by cytokine cascade 
and mononuclear infiltration  [28-30]. Recent studies 
had shown elevation of HMGB-1 in a mice model of 
Caerulein induced acute pancreatitis, and inhibition 
of HMGB-1 attenuated the severity of the pancreatitis 
[30]. In our study, the inhibition of translocation of 
HMGB-1  from  nucleus  to  cytoplasm  was  consistent 
with the recent report that Cis inhibits HMGB-1 re-
leasing from nucleus of mononuclear cell in IR liver 
[31-33]. However the fate that we observed the reduc-
tion of HMGB-1 in graft extract of Cis treated groups 
was unexpected. This might be at least in part due to 
the  reduction  of  the  numbers  of  inflammatory  cells 
infiltration into the graft. Whether Cis is able to sup-
press protein expression of HMGB-1 is subjected to 
further investigation. 
Cis as general chemotherapeutic agent has been 
used  in  a  range  of  doses  from  pharmacological  to 
toxicological levels depending on their applications. 
Previous  study  showed  that  Cis  at  doses  up  to 
10mg/kg did not alter liver or kidney function com-
pared to normal saline solution [9]. On the other hand, 
other studies have shown that Cis at a single dose of 
10 mg/kg is clearly nephrotoxic and hepatotoxic. In 
our study, a relatively higher dose of Cis (10mg/kg) 
appears not lead to a better treatment outcome.  
While our study is able to show the protective 
effect of PTP at a dose of 1mg/kg, we were also una-
ble to show a dose dependent effect for some of the 
assays. This may be due to the sensitivity of methods 
used and the systemic toxic effects of Cis at high doses 
in the individual recipient mice. It is also possible due 
to the fate that a single time point of 6 hours study 
after reperfusion is not sufficient to monitor the entire 
development of IR induced PTP. While we showed 
the evidence that pretreatment of Cis in recipients is 
able to attenuate graft pancreatitis by the inhibition of 
inflammation, these limitations in the study will fur-
ther promote us to clarify the mechanism of Cis action 
in vitro.  
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